Cognition Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Clinical-stage biopharmaceutical company developing small-molecule treatments for age-related diseases of the central nervous system and retina. This unaudited filing covers the quarter and six months ended June 30, 2023; comparatives are the same periods in 2022. Its lead candidate is CT1812. The company reported no product-sales revenue; grant income is presented as other income.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development expense | $8.5 million | $9.1 million | $13.9 million | $15.6 million |
| General and administrative expense | $3.3 million | $3.1 million | $6.9 million | $6.0 million |
| Total operating expenses | $11.8 million | $12.2 million | $20.8 million | $21.6 million |
| Grant income | $6.9 million | $6.4 million | $10.4 million | $12.3 million |
| Net loss | $4.7 million | $5.8 million | $10.9 million | $9.6 million |
| Net loss per share, basic and diluted | $0.16 | $0.25 | $0.37 | $0.43 |
At June 30, 2023, cash and cash equivalents were $37.2 million, down from $41.6 million at year-end 2022. Current assets were $41.6 million and current liabilities $7.9 million. Total liabilities were $9.6 million, including $0.8 million of operating lease liabilities; the $0.2 million insurance-premium financing balance was current. No material conventional long-term borrowing was reported.
For the first six months, operating cash use was $6.4 million, investing cash use $0.1 million, and financing cash provided was $2.1 million, primarily from ATM stock sales. Cash decreased $4.4 million. No operating margin is meaningful because the company had no product revenue and reported an operating loss.
Changes versus prior comparable periods
- Q2 net loss narrowed by about $1.0 million, chiefly as operating expenses declined and grant income and money-market interest increased.
- Six-month net loss widened by $1.3 million: lower operating expenses were more than offset by a $1.9 million decline in grant income and higher other expense.
- Six-month R&D spending fell $1.7 million, mainly due to lower clinical-trial start-up and manufacturing costs; personnel and preclinical spending increased. G&A rose $0.9 million, including professional fees and equity compensation.
- Operating cash use improved from $8.3 million to $6.4 million. The company raised $2.5 million gross through its ATM, issuing 1.1 million shares; 30.3 million shares were outstanding at June 30, versus 29.0 million at December 31, 2022.
Outlook, commentary, risks, and unusual items
- Management said cash and expected non-dilutive grant income should fund operating expenses and capital expenditures through the third quarter of 2024, assuming no use of remaining ATM capacity or the Lincoln Park equity line. The notes separately state cash is expected to fund operations for at least one year after filing. Additional funding will be needed beyond that period.
- The ATM had approximately $37.5 million of capacity remaining. A Lincoln Park agreement permits, but does not require, the company to sell up to $35 million of stock over 36 months; no shares had been sold under it by June 30. Further equity financing may dilute shareholders; access to grants, financing, or partnerships is not assured.
- Management expects significant expenses and losses to continue and says it cannot predict when, or whether, profitability will be achieved. Funding needs depend on clinical progress, trial costs, grants, manufacturing, regulatory review, and commercialization plans.
- Management cited SNAP findings that a single oral CT1812 dose rapidly displaced amyloid-beta oligomers from synapses in people with Alzheimer’s disease, and SEQUEL topline results indicating improved synapse activity and brain-region connectivity after four weeks. These are clinical findings, not regulatory approval or evidence of commercial revenue.
- Key risks include dependence on CT1812, clinical and regulatory uncertainty, reliance on third-party manufacturers and trial vendors, grant reimbursement eligibility and audits, and the need for further capital. Grants awarded had project periods extending through May 31, 2026, subject to extension; unallowable costs or grant noncompliance could prevent reimbursement or require repayment.
- No material litigation or reasonably possible material loss contingency was reported. The filing reported no material change to the prior annual report’s risk factors and stated disclosure controls and internal control over financial reporting were effective.
Important facts for investors to verify
- Whether CT1812 trial results and timelines support the company’s development plans, and whether further data validate the SNAP and SEQUEL findings.
- Whether grant awards remain available and reimbursable, and whether expected grants support the stated runway estimate.
- Actual cash burn and financing needs relative to the stated Q3 2024 runway, including any ATM or Lincoln Park share sales and resulting dilution.
- Clinical-trial, manufacturing, regulatory, or other developments that could increase spending or delay programs; the filing gives no product-revenue guidance.